Clinical Research Directory

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer(NSCLC) that is anaplastic lymphoma kinase (ALK)-postive as assessed by the next-generation sequencing (NGS) test. * Confirmed diagnosis of brain metastases or suspected brain metastases * Iruplinalib is proposed for treatment * Eastern Cooperative Oncology Group(ECOG) Performance Status of 0-1 * Adequate organ and marrow function Exclusion Criteria: * Have serious gastrointestinal disease or other uncontrolled internal diseases and infections * The presence of mental illness or substance abuse at the time of screening that may have affected compliance with the trial * The presence of pleural fluid or ascites that requires treatment or is judged by the investigator to be uncontrollable at the time of screening * Arterial/venous thrombosis events occurred within 6 months prior to administration, such as cerebrovascular accidents, deep vein thrombosis, and pulmonary embolism